About Us
Profile
Novelwise Pharmaceutical Corporation was formerly the new drug research and development department of NatureWise Biotech & Medicals Corporation. As our new drug development projects reached significant milestones, the R&D department was established as a separate entity in 2023 to expedite its progress. For years, our commitment has been to pioneer innovative medicines through rigorous independent research and strategic partnerships, addressing unmet medical needs. Embracing a new era, Novelwise isdedicated to enhancing corporate competitiveness by developing innovative treatments for disease eradication. Headquartered in Taiwan, we have a global outlook.
Business Strategy
Leveraging our robust research capabilities, we engage in actively collaborate with the academic community to explore niche markets and identify promising target products. Through a thorough assessment of market dynamics, regulations frameworks, and scientific advancements, formulate optimal development strategies for drug candidates aimed at addressing diseases in need of enhanced treatment modalities. Our goal is to tackle unmet medical needs by spearheading the development of innovative drugs and offering solutions that prioritize efficacy, safety, and patient convenience.
R & D
Products
NBM-BMX Capsule
NBM-BMX is a novel chemical compound designed to specifically inhibits the HDAC 8 protein. The developing isoform-selective HDAC inhibitors has become crucial due to the observed side effects limiting the clinical application of FDA-approved non-selective HDAC inhibitors. NBM-BMX demonstrates exceptional tumor inhibitory activity across various cancer types, particularly those exhibiting high expression levels of HDAC8 protein. Novelwise holds global rights to NBM-BMX, including manufacturing and sales. The phaseIb/II clinical trial for newly diagnosed GBM is ongoing.
